Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Tevogen.AI (NASDAQ: TVGNW) announced an expanded collaboration with Microsoft and Databricks to develop the beta version of its PredicTcell™ model, focusing on oncology applications. The initiative builds upon their recently published international patent (WO 2025/129197) for predicting immunologically active peptides.
The enhanced model will combine a new oncology dataset with existing virology data to improve prediction accuracy for cancer and infectious disease therapies. Led by CIO Mittul Mehta, Tevogen.AI aims to address the challenges in oncology drug discovery, particularly the complexity of the disease and limited high-quality datasets.
Tevogen.AI (NASDAQ: TVGNW) ha annunciato una collaborazione ampliata con Microsoft e Databricks per sviluppare la versione beta del suo modello PredicTcell™, con focus sulle applicazioni oncologiche. L'iniziativa si basa sul loro brevetto internazionale recentemente pubblicato (WO 2025/129197) per la previsione di peptidi immunologicamente attivi.
Il modello potenziato combinerà un nuovo dataset oncologico con i dati virologici esistenti per aumentare la precisione delle previsioni per terapie contro il cancro e le malattie infettive. Guidata dal CIO Mittul Mehta, Tevogen.AI punta a risolvere le sfide nella scoperta di farmaci in oncologia, in particolare la complessità della malattia e la limitata disponibilità di dataset di alta qualità.
Tevogen.AI (NASDAQ: TVGNW) anunció una colaboración ampliada con Microsoft y Databricks para desarrollar la versión beta de su modelo PredicTcell™, centrada en aplicaciones oncológicas. La iniciativa se apoya en su patente internacional recientemente publicada (WO 2025/129197) para predecir péptidos inmunológicamente activos.
El modelo mejorado combinará un nuevo conjunto de datos oncológicos con los datos virológicos existentes para mejorar la precisión de las predicciones en terapias contra el cáncer y enfermedades infecciosas. Bajo la dirección del CIO Mittul Mehta, Tevogen.AI pretende abordar los retos del descubrimiento de fármacos en oncología, en particular la complejidad de la enfermedad y la escasez de conjuntos de datos de alta calidad.
Tevogen.AI (NASDAQ: TVGNW)는 Microsoft 및 Databricks와의 협력을 확대하여 PredicTcell™ 모델의 베타 버전을 암(종양학) 응용에 중점을 두고 개발한다고 발표했습니다. 이 이니셔티브는 면역학적으로 활성인 펩타이드를 예측하는 최근 공개된 국제 특허(WO 2025/129197)를 바탕으로 합니다.
강화된 모델은 새로운 암 관련 데이터셋을 기존의 바이러스학 데이터와 결합하여 암 및 감염병 치료제 예측의 정확도를 향상시킬 것입니다. CIO Mittul Mehta의 주도 아래 Tevogen.AI는 질병의 복잡성과 고품질 데이터셋의 부족 등 종양학 신약 발굴의 난제를 해결하는 것을 목표로 하고 있습니다.
Tevogen.AI (NASDAQ: TVGNW) a annoncé une collaboration élargie avec Microsoft et Databricks pour développer la version bêta de son modèle PredicTcell™, axée sur les applications en oncologie. L'initiative s'appuie sur leur brevet international récemment publié (WO 2025/129197) visant à prédire des peptides immunologiquement actifs.
Le modèle amélioré combinera un nouveau jeu de données oncologiques avec des données virologiques existantes afin d'améliorer la précision des prédictions pour les thérapies contre le cancer et les maladies infectieuses. Sous la direction du CIO Mittul Mehta, Tevogen.AI vise à relever les défis de la découverte de médicaments en oncologie, notamment la complexité de la maladie et la rareté de jeux de données de haute qualité.
Tevogen.AI (NASDAQ: TVGNW) hat eine erweiterte Zusammenarbeit mit Microsoft und Databricks angekündigt, um die Beta-Version seines PredicTcell™-Modells zu entwickeln, mit Fokus auf onkologische Anwendungen. Die Initiative baut auf ihrem kürzlich veröffentlichten internationalen Patent (WO 2025/129197) zur Vorhersage immunologisch aktiver Peptide auf.
Das verbesserte Modell wird einen neuen Onkologie-Datensatz mit vorhandenen Virologie-Daten kombinieren, um die Vorhersagegenauigkeit für Krebs- und Infektionskrankheiten-Therapien zu erhöhen. Unter der Leitung von CIO Mittul Mehta will Tevogen.AI die Herausforderungen in der onkologischen Wirkstoffforschung angehen, insbesondere die Komplexität der Erkrankung und die begrenzte Verfügbarkeit hochwertiger Datensätze.
- Expansion of AI capabilities into oncology, a high-value therapeutic area
- Strategic collaboration with major tech companies Microsoft and Databricks
- International patent protection for machine learning systems
- Potential new revenue stream through external market opportunities
- Need to raise additional capital to execute business plan
- Limited operating history and early development stage
- Significant regulatory and development risks
- Faces intense competition in rapidly evolving tech and biotech sectors
Insights
Tevogen.AI expands its AI model to oncology applications, leveraging Microsoft and Databricks partnerships to potentially create new revenue streams.
Tevogen's expansion of its AI initiative into oncology marks a strategic diversification from its initial virology focus. By building upon the alpha version of PredicTcell with Databricks' Data Intelligence Platform and Microsoft's infrastructure, the company is positioning itself at the intersection of two high-growth markets: AI-powered drug discovery and cancer therapeutics.
The patent application (WO 2025/129197) mentioned in the release provides crucial intellectual property protection for their machine learning systems that predict immunologically active peptides. This technical foundation is especially valuable for targeted cancer therapy development, where identifying the right peptides can dramatically improve treatment efficacy.
Most notably, Tevogen explicitly states intentions to explore external market opportunities as potential revenue sources. This suggests a possible SaaS or platform licensing model where their AI capabilities could be monetized beyond internal drug development programs, potentially creating a dual revenue stream architecture: one from eventual therapeutic products and another from technology licensing.
The oncology expansion is particularly strategic because cancer immunotherapy development faces significant challenges in target identification. If PredicTcell can effectively predict cancer-specific peptides that elicit immune responses, it could substantially reduce the time and cost of bringing new oncology treatments to market - both for Tevogen and potential commercial partners.
While the alpha version demonstrated initial capabilities, expanding the training dataset to include oncology data will likely enhance the model's predictive accuracy and breadth of applications, potentially accelerating Tevogen's internal R&D pipeline while creating licensing opportunities in the highly lucrative oncology space.
- Tevogen.AI to explore external market opportunities as a potential revenue source.
- Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development.
- Tevogen.AI to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams.
WARREN, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model.
Powered by the Databricks Data Intelligence Platform and backed by their innovative engineering teams, Tevogen.AI has begun curating a dataset focused on oncology. The dataset, aggregated with the initial virology dataset. aims to improve upon the accuracy of the alpha version of PredicTcell model.
This next phase of development builds on Tevogen.AI’s recently published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases.
“We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model,” said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. “Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets.”
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is Tevogen.AI's PredicTcell™ model and what is its purpose?
How is Microsoft involved in Tevogen.AI's development of PredicTcell™?
What patent protection does Tevogen.AI have for PredicTcell™?
What are the main challenges Tevogen.AI faces in developing PredicTcell™?
How does Tevogen.AI plan to monetize the PredicTcell™ platform?
